To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Inclusion Criteria: * Able and willing to provide a written informed consent * 18 years of age or older, of either gender * Has a diagnosed malignant solid tumor through histological or cytological examination * Has never been treated with chemotherapy (Antitumor drugs are not used for cancer treatment, or intravesical instillation therapy for bladder cancer is not regarded as chemotherapy) * Receive the first course of cisplatin-based chemotherapy * Has a performance status (ECOG scale) of 0 to 2 * Predicted life expectancy of ≥ 3 months Exclusion Criteria: * .Subjects with poor blood pressure control after medication * Subjects with symptomatic brain metastases or any symptoms suggestive of brain metastasis or intracranial hypertension * Subjects with a history of severe cardiovascular diseases within 3 months prior to the administration of cisplatin, such as acute myocardial infarction, NYHA class II-IV heart failure, etc. * Subjects with a history of severe torsional ventricular tachycardia, QTcF\>480 ms * Subjects with mental disabilities or severe emotional or mental disorders, The investigators determined that inappropriate for participation in this clinical trial * Inadequate bone marrow, kidney, and liver function 10. Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -7 through Day 6 * Scheduled to receive moderately or highly emetogenic chemotherapy from Day 2 through Day 6 * Subjects who have experienced emetic events (vomiting or dry …